Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Respir Crit Care Med ; 181(5): 429-37, 2010 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-20007928

RESUMEN

RATIONALE: The mechanism of action of diethylcarbamazine (DEC), an antifilarial drug effective against tropical pulmonary eosinophilia, remains controversial. DEC effects on microfilariae depend on inducible NO synthase (iNOS). In eosinophilic pulmonary inflammation, its therapeutic mechanism has not been established. We previously described the rapid up-regulation of bone marrow eosinophilopoiesis in ovalbumin (OVA)-sensitized mice by airway allergen challenge, and further evidenced the down-regulation of eosinophilopoiesis by iNOS- and CD95L-dependent mechanisms. OBJECTIVES: We investigated whether: (1) DEC can prevent the effects of airway challenge of sensitized mice on lungs and bone marrow, and (2) its effectiveness depends on iNOS/CD95L. METHODS: OVA-sensitized BALB/c mice were intranasally challenged for 3 consecutive days, with DEC administered over a 12-, 3-, or 2-day period, ending at the day of the last challenge. We evaluated: (1) airway resistance, cytokine (IFN-gamma, IL-4, IL-5, and eotaxin) production, and pulmonary eosinophil accumulation; and (2) bone marrow eosinophil numbers in vivo and eosinophil differentiation ex vivo. MEASUREMENTS AND MAIN RESULTS: DEC effectively prevented the effects of subsequent challenges on: (1) airway resistance, Th1/Th2 cytokine production, and pulmonary eosinophil accumulation; and (2) eosinophilopoiesis in vivo and ex vivo. Recovery from unprotected challenges included full responses to DEC during renewed challenges. DEC directly suppressed IL-5-dependent eosinophilopoiesis in naive bone marrow. DEC was ineffective in CD95L-deficient gld mice and in mice lacking iNOS activity because of gene targeting or pharmacological blockade. CONCLUSIONS: DEC has a strong impact on pulmonary eosinophilic inflammation in allergic mice, as well as on the underlying hemopoietic response, suppressing the eosinophil lineage by an iNOS/CD95L-dependent mechanism.


Asunto(s)
Enfermedades de la Médula Ósea/tratamiento farmacológico , Dietilcarbamazina/farmacología , Eosinofilia/tratamiento farmacológico , Proteína Ligando Fas/fisiología , Filaricidas/farmacología , Óxido Nítrico Sintasa de Tipo II/fisiología , Eosinofilia Pulmonar/tratamiento farmacológico , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Broncoconstrictores/farmacología , Eosinófilos/efectos de los fármacos , Hematopoyesis/efectos de los fármacos , Interferón gamma/biosíntesis , Interleucina-4/biosíntesis , Interleucina-5/biosíntesis , Recuento de Linfocitos , Cloruro de Metacolina/farmacología , Ratones , Ratones Endogámicos BALB C
2.
Cephalalgia ; 25(7): 542-4, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15955042

RESUMEN

We compared the frequency of migraine among Sydenham's chorea (SC) patients, rheumatic fever (RF) patients without neurological symptoms and matched controls. Migraine was more frequent in SC patients (12/55, 21.8%) than in controls (9/110, 8.1%) and as common as in the RF group (10/55, 18.2%). Our data are in agreement with previous studies reporting higher frequency of migraine in other basal ganglia disorders, such as essential tremor and Tourette's syndrome.


Asunto(s)
Corea/epidemiología , Trastornos Migrañosos/epidemiología , Fiebre Reumática/epidemiología , Medición de Riesgo/métodos , Adolescente , Brasil/epidemiología , Corea/diagnóstico , Comorbilidad , Femenino , Humanos , Incidencia , Masculino , Trastornos Migrañosos/diagnóstico , Fiebre Reumática/diagnóstico , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA